Conferences - Results from #180

IBCN 2024: GUSTO Trial September 21, 2024

IBCN 2024: ADC Toxicity, Management and Clinical Trial Updates September 21, 2024

IBCN 2024: Benefit of Whole-Pelvis Radiation for Patients with Muscle Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis September 21, 2024

IBCN 2024: Influence of Immortal Time Bias and Conditional Survival on the Comparison of Radical Cystectomy Versus Trimodality Therapy for Muscle Invasive Bladder Cancer September 21, 2024

IBCN 2024: Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Preliminary Analysis from the BOND-003 Trial September 21, 2024

IBCN 2024: EG-70 (Detalimogene Voraplasmid), a Novel, Non-Viral, Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS: Preclinical Characterization and Translation into the Clinic September 21, 2024

IBCN 2024: Augmented Cystoscopy with Deep Learning September 21, 2024

IBCN 2024: The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer September 21, 2024

IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Patients with BCG Unresponsive High-Risk NMIBC: Results from SunRISe-1 September 21, 2024

IBCN 2024: TAR-200 Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients With Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy: Interim Analysis of SunRISe-4 September 21, 2024

IBCN 2024: AI in Bladder Cancer: The Good, the Bad, and the Ugly September 21, 2024

IBCN 2024: A Randomized Phase II Trial Comparing Single Dose Perioperative Instillation of Intravesical Gemcitabine Versus Mitomycin-C Following Complete Resection of Non-Muscle Invasive Bladder Cancer: Evaluation of Efficacy and Tolerance September 20, 2024

IBCN 2024: AI-Enabled Bladder Cancer Grading: Externally Validating Quantitative Nuclear Features and Demonstrating Their Potential to Better Predict Time to Recurrence September 20, 2024

IBCN 2024: Validation of Artificial Intelligence-Powered Pathology Assay and Comparison to EAU 2021 Guidelines on Prediction of Muscle Invasive Progression Post BCG in an International 12 Center Cohort September 20, 2024

IBCN 2024: Circulating Immune-Modulators of Response to Neoadjuvant Nivolumab + Nab-Paclitaxel in Muscle Invasive Bladder Cancer: Biomarker Analyses from Nure-COMBO Trial September 20, 2024

IBCN 2024: Investigating BCG Induced B Cell Responses in Patients with Non-Muscle Invasive Bladder Cancer September 20, 2024

IBCN 2024: Correlation of ctDNA Dynamics with Clinical Response in MIBC Patients Undergoing Trimodality Therapy September 20, 2024

IBCN 2024: Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy September 20, 2024

IBCN 2024: Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder: Results from the Multicenter OPTIMUS Umbrella Study September 20, 2024

IBCN 2024: Undetectable ctDNA Status Before Radical Cystectomy Predicts Improved Outcomes September 20, 2024

Page 10 of 594